EN DE
Watch Bruker Corporation for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Bruker Corporation (BRKR) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Bruker Corporation stock $2.87, price $61.59, that is 95.3% below the price, quality 34 out of 100. Rating: strongly overvalued. Calculated from audited financials with 14 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN US1167941087

BC Bruker Corporation logo Thin data Nov 15, 2026

Bruker Corporation

BRKR · US

Far too expensive (fair value 95% below the price) and weak company, but rising price: meets 1 of 3 rules.

Get notified free when this changes
Rising price (uptrend) 
Generates free cash flow 
0.1% dividend yield · Cash covered
Recent news very positive 
Mixed Growth (revenue 5y +11.6 %/yr in USD) 
Loss only from goodwill write-downs · -3.5% net margin (TTM) · excl. goodwill write-downs +5.3% 
Moderate debt 
Insiders sold $648,574 (6M) 
Fair value $2.87 · Strongly overvalued 
Quality 34/100 
Trails peers (4/14) 
Narrow moat 28/100
Thin data 
Special item

Main risks:

🚩Thermo Fisher competition in mass spec🚩Dependence on academic research funding
Watch Bruker Corporation for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$93.36 $29.21 Fair Value $2.87 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 15, 2026.

How to read this chart

60‑month range $29.21 – $93.36 · fair‑value band $1.22 – $6.92 · the $61.59 price screens above the $2.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 15, 2026.

Follow Bruker in your weekly email

Every Wednesday you see whether Bruker is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Show moreShow less

The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions.

It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment.

In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation.

Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Stock analysis

Bruker Corporation (BRKR) currently trades at $61.59, while our model-based Fair Value estimate is $2.87, 95% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $14.89 per share, and 0 of the 13 models we run sit above the $61.59 price.

Bear case: the Earnings-Based group reads lowest at $2.87, and 13 of the 13 models stay below the price. Data coverage for this calculation is low.

Scenario range: $1.22 (bear) to $6.92 (bull), the price of $61.59 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bruker Corporation reported revenue of $3.4B in FY2025 versus $2.4B in FY2021, a compound +9.2%/yr. Reported net income was −$8.6M in FY2025.

Key figures

Market cap $9.4B Mid · P/S ratio 2.52 · EPS (TTM) $−1.10 · Dividend yield 0.1% · Net margin −3.5% · Return on equity −4.8% · Return on assets (EBIT) 8.3% (5-year average) · Operating margin 9.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).

What moves the price

The share trades about 7% below its 52-week high and 88% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −95%, BRKR screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($0.0400 to $30.48). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $1.22 Fair Value $2.87 Bull $6.92
Price $61.59 · Downside -95.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF n/a $1.35 >$5.40 77
Growth DCF n/a $0.8200 >$3.28 75
Owner Earnings n/a n/a $2.99 73
All 14 models by family
DCF Models
FCF DCF n/a $1.35 >$5.40 77
Owner Earnings n/a n/a $2.99 73
5Y Revenue Exit $1.09 $10.56 $23.48 64
5Y EBITDA Exit $10.60 $29.85 $54.10 71
10Y Revenue Exit n/a $6.99 $19.38 64
10Y EBITDA Exit $5.23 $20.15 $43.08 62
Earnings-Based
EPV $1.22 $2.87 $4.26 69
Multiples
EV/EBIT $8.30 $14.89 $21.47 63
EV/EBITDA $20.00 $30.48 $40.96 66
EV/Revenue $2.65 $8.69 $14.73 49
Asset-Based
NCAV (Graham) $0.0300 $0.0400 $0.0600 54
Growth DCF
Growth DCF n/a $0.8200 >$3.28 75
Rev-Margin DCF $1.09 $10.23 $21.81 65
Economic Profit
ROIC Compounder $1.22 $2.87 $4.26 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 25
How much profit the company makes from its sales and capital
Quality Growth 23
Are margins and returns getting better?
Cashflow 15
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 32
Does it invest with discipline instead of growing at any price?
Low Volatility 21
How calm the share price moves, does not count
Price momentum 75
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 85
Distance to the 52-week high, does not count
New shares 75
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 2 officers or directors sold shares worth $648,574 and none bought.

  • SaleMark MunchEXEC VP&PRES BRUKER NANO INC.11× since Jan 5, 2026: 58,843 shares, avg. $49.75$2.9MSep 15, 202610b5-1 plan
  • SaleWolfgang PuschPresident BMID Group3,473 shares at $56.90$197,614Aug 17, 2026
  • SaleRichard A PackerDirector5,028 shares at $48.38$243,255Dec 1, 2025

Plus 16 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 13, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +7.8% a year
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
12.5% (2020) → 6.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+64.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.7%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +60.2% a year for the price and +1.3% for the forecasts.
Forecast 2026 (sales)+3.5%
Forecast 2027 (sales)+4.2%
Projected 2028 (sales)+3.9%
Projected 2029 (sales)+3.6%
Projected 2030 (sales)+3.4%

BRKR screens overvalued: fair value 95% below the price. Compare with Abbott Laboratories, →

Recent news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
Note from the team Oct 11, 2026
AI conclusion: Bruker’s timsTOF platform shows strength in resolving protein variants for drug discovery and biomarker research, yet negative net income and goodwill impairment indicate limited durable advantage overall.
Main risk: Competition from Thermo Fisher's Astral and Orbitrap instruments could force Bruker to lower prices or lose share in proteomics and mass spectrometry sales.
Bull case: By leveraging its timsTOF leadership and AI-enhanced software, Bruker could capture more recurring revenue from biopharma and expand into clinical applications despite competitive pressures.
Bear case: If academic funding remains weak and competitors gain further ground in proteomics, instrument sales could stagnate and margins come under sustained pressure from price competition.
Bruker’s timsTOF systems power a new draft atlas mapping 179,000 proteoforms in human plasma. The work demonstrates the platform’s strength in resolving protein variants for drug discovery and biomarker research. Will these capabilities expand recurring revenue from installed instruments and software or stay mostly tied to academic projects?
Join the discussion →

Compare Bruker Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 400 stocks

Beats the industry median on 4/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −95.3% · Bottom 25%
Profitability
Return on assets −0.1% · Above median
Net margin (12 months) −3.5% · Below median
Operating margin (12 months) 9.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 1.6% · Below median
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.75× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.82× · Pricier than median
P/S (12 months) 2.67× · Cheaper than median
Price / free cash flow (fiscal year) 216.5× · Priciest 25%
EV/EBITDA 18.7× · Pricier than median
PEG 1.52× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 16
FUTURE (revenue growth)8 · sector 41
PAST (return on equity)0 · sector 0
HEALTH (low debt)62 · sector 97
DIVIDEND (yield)2 · sector 34

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥202.57 +13% vs BRKR
Boston Scientific Corporation BSX $44.34 $49.64 +12% vs BRKR
Stryker Corporation SYK $309.64 $343.63 +11% vs BRKR
STERIS plc STE $264.32 $281.90 +7% vs BRKR
DexCom, Inc DXCM $83.33 $88.38 +6% vs BRKR
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs BRKR
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs BRKR
Medtronic plc MDT $102.86 $74.90 −27% vs BRKR
Abbott Laboratories, ABT $108.52 $75.28 −31% vs BRKR
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs BRKR

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bruker Corporation: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Bruker Corporation Fair Value". https://www.fairvalue-calculator.com/stock/BRKR

Frequently asked questions

Is Bruker Corporation (BRKR) overvalued or undervalued?
As of Nov 15, 2026, our model estimates a fair value of $2.87 versus a price of $61.59, about 95% lower (overvalued).
What is the fair value of BRKR?
Our model-based fair value for Bruker Corporation is $2.87 (as of Nov 15, 2026), built from audited fundamentals. The current price: $61.59.
What is the quality score of BRKR?
Bruker Corporation has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bruker Corporation (BRKR)?
Our model-based price target is the fair value of $2.87 (as of Nov 15, 2026) from 14 valuation models. Cautious scenario $1.22, optimistic scenario $6.92. It is a calculation from audited fundamentals, not an analyst target.
What is the Bruker Corporation stock forecast for 2026?
Our models put fair value at $2.87, about 95% lower versus a price of $61.59 (overvalued). Cautious scenario $1.22, optimistic scenario $6.92. The calculation is refreshed regularly with new filings.
What is the revenue of Bruker Corporation (BRKR)?
Bruker Corporation reported trailing-twelve-month revenue of about $3.5B (latest available figure, as of Nov 15, 2026).
Does Bruker Corporation pay a dividend?
Bruker Corporation currently shows a dividend yield of 0.08% relative to its recent price (as of Nov 15, 2026).
How much is the dividend of Bruker Corporation (BRKR) and when is the ex-dividend date?
Bruker Corporation pays a dividend of $0.05 per share a year, a dividend yield of 0.1%. The last ex-dividend date was Sep 21, 2026. A dividend has been paid every year since at least 2016. Free cash flow covers the dividend 5.68 times. Our assessment: Cash covered. The dividend is fully funded by free cash flow. The payout ratio on earnings is not available for this company.
What growth is priced into Bruker Corporation (BRKR)?
For today's price to be fair in a discounted-cash-flow model, Bruker Corporation would have to grow free cash flow by 64.0 % per year for five years (discount rate 10.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew 11.6 % per year. As of Nov 15, 2026.
What discount rate (WACC) does the fair value of BRKR use?
Our models discount Bruker Corporation at 10.4 %: a base by market capitalisation (mid), damped by beta 1.27, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bruker Corporation that is +64.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.4 %) and the same formula as our fair value.
How much growth has Bruker Corporation (BRKR) delivered so far?
Over the past 5 years revenue at Bruker Corporation grew 11.6 % a year. The price currently implies free-cash-flow growth of +64.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bruker Corporation (BRKR) growing?
The median revenue growth in the sector is +5.8 % a year. That is the yardstick for the growth priced into Bruker Corporation (+64.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bruker Corporation (BRKR)?
The free-cash-flow yield on the price is 0.46 %: that much free cash flow Bruker Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bruker Corporation (BRKR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bruker Corporation it is $2.87 per share (as of Nov 15, 2026), against a price of $61.59. It is the blended result of 14 valuation models in 6 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Bruker Corporation stock overvalued or undervalued in 2026?
As of Nov 15, 2026, BRKR trades above its calculated fair value: price $61.59, fair value $2.87, a gap of about −95% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRKR?
No. The price is what the market pays today ($61.59); the fair value is what the company's own numbers justify ($2.87). For Bruker Corporation the two are $58.72 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bruker Corporation worth?
The market values Bruker Corporation at about $9.4B (market capitalisation, as of Nov 15, 2026). Per share that is $61.59; our models calculate a fair value of $2.87 per share.
What do the bullish and bearish scenarios say about BRKR?
Our models span a range for Bruker Corporation: cautious scenario $1.22, base $2.87, optimistic $6.92 per share (as of Nov 15, 2026, price $61.59). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BRKR?
The PEG ratio of Bruker Corporation is 1.52 (P/E divided by earnings growth, as of Nov 15, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bruker Corporation (BRKR)?
Balance-sheet figures for Bruker Corporation (as of Nov 15, 2026): return on equity −4.8%, debt of 0.75 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is BRKR from its 52-week high?
Bruker Corporation trades at $61.59, about 7% below its 52-week high of $66.54 and 88% above the low of $32.68 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of $2.87 is for.
Which stocks are comparable to Bruker Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bruker Corporation stock attractive at the current price?
The data as of Nov 15, 2026: price $61.59, calculated fair value $2.87 (−95%), Quality Score 34/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRKR calculated?
We run Bruker Corporation through 14 models from 6 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $2.87 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Bruker Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bruker Corporation (BRKR)?
The closing price on Nov 13, 2026 was $61.59. Our model-based fair value is $2.87, about 95% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bruker Corporation right now?
The price sits above even our optimistic bull case ($6.92). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($1.22 to $6.92). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Bruker Corporation (BRKR) come from?
Earnings per share at Bruker Corporation grew 13.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.2 %, EBIT margin +3.0 %, tax rate −0.9 %, residual (interest, one-offs) +1.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Bruker Corporation

How large is the market capitalisation of Bruker Corporation (BRKR)?
The market capitalisation of Bruker Corporation is $9.4B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bruker Corporation (BRKR)?
The price-to-sales ratio of Bruker Corporation is 2.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bruker Corporation (BRKR)?
Earnings per share at Bruker Corporation are $−1.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bruker Corporation (BRKR)?
The dividend yield of Bruker Corporation is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bruker Corporation (BRKR)?
The net margin of Bruker Corporation is −3.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bruker Corporation (BRKR)?
The return on equity (ROE) of Bruker Corporation is −4.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bruker Corporation (BRKR)?
On an EBIT basis the return on assets of Bruker Corporation is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bruker Corporation (BRKR)?
The operating margin of Bruker Corporation is 9.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bruker Corporation (BRKR)?
Revenue at Bruker Corporation is growing 1.6% versus a year earlier (3y avg +10.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bruker Corporation (BRKR)?
Earnings per share at Bruker Corporation are down 81.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bruker Corporation (BRKR) carry?
The net debt of Bruker Corporation is $1.7B (fiscal year 2025, ≈ 40.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bruker Corporation in the live analysis

One click puts Bruker Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.